A -Development and maintenance of leukemia can partially be attributed to alterations in (anti) apoptotic gene expression. Genome-wide transcriptome analyses revealed that apoptosis-associated genes were di erentially expressed between patient acute myeloid leukemia (AML) CD + cells and normal bone marrow (NBM) CD + cells. Amongst these, TGF-β activated kinase (TAK ) was strongly upregulated in AML CD + cells. Genetic downmodulation or pharmacologic inhibition of TAK activity strongly impaired primary AML cell survival and cobblestone formation in stromal co-cultures. TAK inhibition was mainly due to blockade of the NF-κB pathway, as TAK inhibition resulted in reduced levels of p-IκBα and p activity. Overexpression of a constitutive active variant of NF-κB partially rescued TAK -depleted cells from apoptosis. Importantly, NBM CD + cells were less sensitive to TAK inhibition compared to AML CD + cells. Knockdown of TAK also severely impaired leukemia development in vivo and prolonged overall survival in a humanized xenogra mouse model. In conclusion, our results indicate that TAK is frequently overexpressed in AML CD + cells, and that TAK inhibition e ciently target leukemic stem/progenitor cells in a NF-κB-dependent manner.
. I Due to a high incidence of relapse, the survival rate of AML patients is still below %, despite intensive treatment with chemotherapy. It is assumed that a small population of quiescent leukemic stem cells (LSCs) with self-renewal properties persists within the bone marrow microenvironment. ese LSCs are responsible for relapse of the disease post-treatment [ , ] , suggesting that current therapies particularly target the more rapidly dividing leukemic blasts, while the LSCs generally survive.
Leukemogenesis of stem cells is a process in which various cellular programs can be a ected, including those that regulate apoptosis and di erentiation [ ].
Modi cation of programmed cell death might be important not only for leukemic transformation but could also contribute to tumor maintenance and chemoresistance. Dysregulation of a number of cell survival pathways, such as BCL , p , and NF-κB, have been associated with aberrations in apoptotic responses of AML cells [ ]. In contrast to normal bone marrow CD + cells, constitutive activation of NF-κB has been observed in AML CD + cells [ -] . In accordance with this activation, NF-κB-associated pathways are related to tumor formation and maintenance [ ]. Pharmacological inhibition of NF-κB by proteasome inhibitors has been reported to induce cell death in the AML CD + CD − subfraction both in vitro and in vivo [ , ] .
TGF-β activated kinase (TAK /MAP K ) is a kinase upstream of NF-κB which can be activated by a variety of cytokines including TNFα, TGF-β and IL-. Subsequently, phosphorylation of TAK leads to downstream activation of several pathways, including the NF-κB, JNK, ERK and p -pathways. roughout embryonic development, TAK is required for angiogenesis and regulates the survival of endothelial cells and normal hematopoietic stem cells (HSCs) [ , ] . A strong reduction of HSCs in TAK − − mice has been observed that can partially be rescued by the knockout of tumor necrosis factor receptor and (TNFR and TNFR ), suggesting that apoptosis upon TAK inhibition is largely mediated by TNFα signaling [ , ] . In various cancer models, including colorectal cancer, skin tumors and mantle cell lymphoma, TAK has been shown to be essential for the survival of cancer cells, where it might a ect tumor metastasis in a WNT-dependent manner [ -] . Furthermore, reduction of TAK activity speci cally induced cell death within all these di erent tumors, both in vitro as well and in vivo. Studies in patients with esophageal squamous cell carcinomas and clear cell renal cell carcinoma have also demonstrated that high TAK expression is associated with unfavorable prognosis [ , ] .
We performed a detailed analysis of the apoptotic programs within the leukemic stem cell enriched CD + fraction of AML patients in comparison to normal CD + stem/progenitor cells. We discovered that TAK expression is elevated in a large subset of AML CD + cells. Pharmacologic or genetic inhibition of TAK induced cell death in AML CD + cells in an NF-κB-dependent manner and signi cantly prolonged survival in vivo. ese results indicate that targeting of TAK could be a potential new strategy in the treatment of AML.
. M . .
-Gene expression pro ling apoptosis related genes was based on previously studies using Illumina HumanHT-Expression BeadChips [ , ] . ese studies included samples and were divided as follows: AML CD + ( in duplicate), and normal bone marrow CD + samples. All samples were corrected for background using Illumina GenomeStudio and then jointly forced to positive values, normalized and transformed using the R packages Bioconductor and Lumi [ , ] . Probes with a detection p-value larger than . in all samples, as provided by GenomeStudio, were deleted. Log transformation and quantile normalization were applied. As a measure of quality control we performed a principal component analysis (PCA) on the correlation matrix of all samples [ ]. e rst component was removed from the data [ ]. To ensure reliability and reproducibility of the results we used multivariate permutations (MP) to determine the signi cance of our results.
A gene list composed of apoptosis-related genes (in total probes) was constructed. is list was largely based on Gene ontology terms (extrinsic apoptotic signaling pathway) and (intrinsic apoptotic signaling pathway) combined with human apoptotic proteins present in the uniprotKB database. Differential expression was considered signi cant at P < .
. Average linkage hierarchical clustering with the centered correlation distance metric was performed using Cluster . and TreeView so ware . Micro-array data have been deposited in GEO, accession number GSE .
http://www.eisenlab.org/eisen/ . . e human promyelocytic leukemia cell line HL-and the human monocytic cell line MOLM were cultured in RPMI supplemented with % FBS. e human monocytic leukemia cell line Oci-AML was cultured in RPMI supplemented with % FBS. e human erythroleukemic cell line TF-was cultured in RPMI supplemented with % FCS and ng/mL GM-CSF (Genetics Institute, Cambridge, MA).
. . ,
Informed consent was obtained to use the AML blasts in accordance with the Declaration of Helsinki; the protocol was approved by the Medical Ethics Committee of the UMCG. AML mononuclear cells were isolated by density gradient centrifugation, and CD + cells were selected by MiniMacs (Miltenyi Biotec, Amsterdam, the Netherlands). erea er cells were expanded on MS stromal cells in long-term culture (LTC) medium (αMEM supplemented with heat-inactivated . % FCS, heat-inactivated . % horse serum (Sigma, Zwijndrecht, the Netherlands), penicillin and streptomycin, mM glutamine, . µM β-mercaptoethanol (Sigma) and µM hydrocortisone (Sigma)) with interleukin (IL-; Gist-Brocades, Del , the Netherlands), granulocyte colony-stimulating factor (G-CSF; Rhone-Poulenc Rorer, Amstelveen, the Netherlands), and thrombopoietin (TPO; Kirin, Tokyo, Japan) ( ng/mL each) as previously described [ , ] . Cultures were kept at ○ C and % CO . Cultures were demipopulated weekly for analysis.
A er achieving informed consent, bone marrow aspirates were obtained from patients who underwent a total hip replacement. e protocol for bone marrow collection was approved by the institutional review board of the University Medical Center Groningen (UMCG). All participants had normal general health, normal peripheral blood counts and did not su er from a haematological disorder.
. . Antibodies were obtained from Beckton Dickinson and Biolegend (Alphen a/d Rijn, the Netherlands). Cells were incubated with antibodies at ○ C for minutes. All uorescence-activated cell sorter (FACS) analyses were performed on a FACScalibur (Becton Dickinson) and data was analyzed using FlowJo . . . Cells were sorted on a MoFLo-XDP or Astrios (DakoCytomation, Carpinteria, CA, USA).
. .
ExtGLuc was retrieved from the rPLSI -ExtGLuc-IRES-hrGFP vector (kindly provided by the Brentjens lab [ ]) by EcoRI/StuI (blunt) and ligated into EcoRI/SalI (blunt) sites of the rd generation lentivector CD B_ _pCDH_MSCV. Lentiviral particles were produced by transient transfection in T cells using pVSV, pREV and pMDL-PRRE helper plasmids. e lentivirus short hairpin RNA vectors targeting human TAK were obtained from Open Biosystems ( ermo Scienti c, Clone ID: TRCN , TRCN , TRCN and TRCN ) targeting the following sequences: AAACAATCCAAGAATCACTGC, TATTAGGATGGTTCACACGGG, ATTCCATCACAAGACACACTG and ATAGTATCATTTGTGGCAGGA. ese hairpins were cloned into the pLKO. lentiviral vector containing GFP (kindly provided by Dr. J. Larsson) or mCherry. e pLKO. GFP vector containing a scrambled (SCR) short hairpin was used as control vector. Lentiviral particles were produced by transient transfection of T cells with the lentiviral expression vectors, and stable transduction of AML cell lines or CD + AML cells was performed, which have both been extensively described [ ]. e retroviral construct pCMV IKKβ S E S E has been described previously [ ]. Retroviral particles were made by transient transfection of PG , and OCI-M cells were transduced with these particles. Transduction e ciency was measured by FACS analysis. Knockdown was investigated by quantitative reverse-transcription-polymerase chain reaction and Western blot.
. .
-κ NF-κB activity was measured by ELISA. ELISA was performed using the TRANS-AM NF-κB p Transcription Factor Assay Kit (Active Motif, North America, Carlsbad, CA) following the manufacturer's recommendations and as described previously [ ].
-κ
T cells were co-transfected with a luciferase vector containing three NF-κB responsive elements (NRE) [ ] together with the MIGR or IKK SSEE vectors. Luciferase assays were performed as described previously [ ].
Migration assay of MOLM cells was performed in a transwell system (Corning Costar, Cambridge, UK) with µm pore size. Two days a er transduction, cells were resuspended in µL medium and added to the upper chamber; µL of medium with and without ng/mL SDF-was added to the lower chamber. Cells were incubated for hours at ○ C and migrated and non-migrated cells were counted.
Eight to ten week old female NSG (NOD.Cg-Prkdcscid ll rgtm Wjl/SzJ) were purchased from the CDP breeding facility within the UMCG. Mouse experiments were performed in accordance with national and institutional guidelines, and all experiments were approved by the Institutional Animal Care and Use Committee of the University of Groningen (IACUC-RuG). Prior to transplantations, mice were sub-lethally irradiated with a dose of . Gy. Following irradiation mice received Neomycin ( . g/l in drinking water) and so food daily for weeks. Mice were lateral tail vein injected with . MOLM luciferase GFP + transduced with SCR or shTAK mCherry lentivirus. Bioluminescence imaging was performed days a er injection of the cells using the IVIS Spectrum, whereby µg of coelenterazine was intravenously injected into the retro-orbital plexus and the mice were imaged for seconds. Bioluminescence was quanti ed using Living Image . . Mice were sacri ced upon detection of clinical signs of disease. Supplemental Methods are available online .
. R . .
+ +
To evaluate the apoptotic programming in LSC-enriched AML CD + cells, transcriptome analyses was performed on a previously established gene expression data set of a large cohort of patient AML CD + cells (n = ) and compared to NBM CD + cells (n = ) [ , ] . Gene set enrichment analysis (GSEA) was performed, which revealed multiple apoptosis-associated sets to be highly enriched in AML CD + cells. In the top signi cantly enriched gene sets, six sets were related to apoptosis, suggesting a major change in apoptotic programming in AML CD + cells compared to normal CD + cells (Figure . A). Next, we determined the apoptosis-associated genes that were di erentially expressed between AML and normal CD + cells by performing transcriptome analysis on apoptosisassociated genes ( Supplementary Table ) . In total, genes were di erentially expressed between AML and normal CD + cells (p < × − ). Supervised cluster analysis using these genes, revealed that AML CD + cells and NBM CD + cells indeed clustered into two groups (Supplementary Figure . ). Interestingly, the expression of various anti-apoptotic as well as pro-apoptotic genes was increased in AML CD + cells compared to NBM CD + ( Supplementary Table ) . A heatmap of the most signi cantly upregulated genes is shown in Figure . B, where the survival-related gene TAK was signi cantly higher expressed in AML CD + cells compared to NBM CD + cells. TAK was previously identi ed as one of the components of the leukemic stem cell-related gene pro le which were signi cantly higher expressed in the AML LSC compared to the non-LSC fraction [ ]. Gene array data for TAK expression in all individual samples is shown in Figure . To study the functional consequences of TAK expression in AML cells, AML cell lines were exposed to the TAK inhibitors z--oxozeaenol and AZ-TAK , which block the phosphorylation and thereby activity of TAK [ ]. Whereas z--oxozeaenol is a resocyclic acid lactone of fungal origin, AZ-TAK has recently been discovered in a small molecule-based lead identi cation to nd compounds that speci cally inhibit TAK phosphorylation. Both compounds inhibit the kinase activity at a nanomolar range ( nM) by binding into the ATP binding pocket [ , , ] .
In the present study we tested the functionality of these inhibitors on the AML cell lines HL , OCI-M and MOLM . Low concentrations of z--oxozeaenol and AZ-TAK resulted in increased apoptosis in most of the cell lines ( Figure . A) and could be promoted further when z--oxozeaenol was combined with TNFα, as previously indicated [ ]. With the AZ-TAK inhibitor, comparable e ects were observed with or without TNF addition; therefore the additional experiments with AZ-TAK were performed without TNF. To con rm the speci city of the e ects, we constructed two independent pLKO. GFP short hairpins targeting TAK . E cient downmodulation of TAK in HL cells was con rmed at the RNA and protein level (Figure . To show that TAKmediated survival was mainly due to decreased NF-κB activation, we transduced the OCI-M cells with IKKβ S E, S E (IKK SSEE) mutant which mimics the active state of p [ ]. Constitutive activation of NF-κB by these construct was detected by a performing a NF-κB luciferase reporter assay. is assay con rmed that expression of IKK SSEE constitutively triggered NF-κB activation in these cells (Supplementary Figure . ). e cell death induced by the TAK inhibitor AZ-TAK was signi cantly reduced (p = . ) upon overexpression of IKK SSEE OCI-AML cells, indicating that NF-κB is an important mediator of the pro-survival pathway downstream of TAK (Figure . D) .
c-FLIP L is one of the anti-apoptotic gene targets of NF-κB and has also been shown to overcome the cell death-inducing e ect of TAK in MEFs [ ]. erefore to determine whether a correlation exists between TAK and cFLIP L , RNA levels of c-FLIP L were measured in shTAK transduced HL cells. Downmodulation of TAK resulted in reduced gene expression levels of cFLIP L (relative expression level is % ± %, p < . ) ( Figure . E) , indicating that c-FLIP L is one of the pro-survival signals provided by the TAK -NF-κB axis. Whereas NF-κB is commonly constitutively activated in AML [ , ], we veri ed whether AML CD + cells expressing high levels of TAK also have increased NF-κB activity by determining IL levels. We observed that AML CD + cells indeed express increased levels of IL ( Supplementary Figure . D) . Nevertheless, TAK levels were not linearly correlated with IL levels (Supplementary Figure . E and . F) and a number of AMLs that expressed low levels of TAK also expressed high levels of IL . is is possibly due to enhanced NF-κB activity that is observed in a wide spectrum of leukemia subtypes which might re ect abnormalities or mutations of activators of NF-κB which activate NF-κB independent of TAK , such as RAS [ ].
. . -+ To assess whether TAK inhibition also a ects the survival of primary AML CD + cells, we investigated the e ectiveness of the TAK inhibitor AZ-TAK on primary AML CD + cells. A er hrs of incubation with AZ-TAK of AML CD + cells, we observed a concentration-dependent e ect on cell death (Figure . A) which equally a ected the AML CD + CD − and CD + CD − cell fraction (data not shown). In line with the reduction of NF-κB activity in AML cell lines upon TAK inhibition, a decrease in NF-κB activity was also seen in AML CD + patient cells a er addition of nM and nM AZ-TAK (n = ) (Figure . B ). More importantly, long-term growth of primary AML CD + cells (n = ) on MS stromal layer was reduced upon addition of nM AZ-TAK (Figure . C) . Moreover, addition of nM AZ-TAK completely abrogated the out-growth of AML CD + cells and no cobblestone formation could be observed under the MS stromal layer (Supplementary Figure . ).
Figure . : Targeting of TAK impairs expansion of primary AML CD + cells
A) Primary AML CD + cells were incubated with various concentrations of AZ-TAK for hrs and cell death was quanti ed by Annexin V staining B) NF-κB activity of primary AML CD + cells treated with nM AZ-TAK . NF-κB activity was measured by p DNA binding ELISA C) Growth of primary AML CD + cells treated with nM AZ-TAK . AZ-TAK was added a er initial growth was observed and added at the indicated time points (↓) D) Growth of primary AML CD + cells transduced with hairpins targeting TAK or control hairpins
To verify the speci city of the e ects, AML CD + cells (n = ) were transduced with both TAK hairpins, and a er days GFP + cells were cultured on MS stromal layer. A signi cant reduction in growth of TAK -hairpin transduced AML cells was observed in time, whereas scrambled transduced cell were able to expand on the stromal cells ( Figure . D) . Also, a reduction of cobblestone frequency was observed in the shTAK AML cell cultures. Loss of suspension and adhesion cells in these long-term assays indicated that the primitive leukemic progenitor and stem cells were targeted in vitro.
To evaluate the e ect of TAK inhibition on the survival of normal hematopoietic cells, NBM CD + cells (n = ) were incubated with nM AZ-TAK for hrs and therea er plated in methylcellulose. TAK inhibition resulted in a fold decrease in CFC numbers (Figure . A) . In line with this data, shTAK transduced cord blood CD + cells also resulted in a fold reduction in CFC numbers when plated in methylcellulose (Figure . B) .
Interestingly, upon treatment with nM AZ-TAK for hrs, a small increase in Annexin V + cells was observed in NBM CD + cells (relative survival is %± %, n = ) upon TAK inhibition. However, the suppressive e ect was signi cantly less pronounced (p < . ) compared to AML CD + cells (n = ) treated for hrs with nM AZ-TAK (Figure . C) . e observed variability in sensitivity between the various AML CD + cells was not related to expression levels of TAK .
Since the bone marrow microenvironment might provide important signals that attenuate the e ects seen upon TAK inhibition, we veri ed the e ect of TAK inhibition on AML cells in vivo. MOLM Gaussia luciferase GFP positive cells were transduced with lentiviral TAK mCherry hairpin or control constructs ( Figure  . A). Two days a er transduction, cells were sorted and intravenously injected into NSG mice (Figure . B) . e e ectiveness of knockdown of TAK mCherry hairpins was veri ed by Q-PCR ( Supplementary Figure . A) . Two weeks a er injection, chimerism levels in peripheral blood were signi cantly lower in shTAK mice compared to SCR mice (Figure . C) . Moreover, luciferase activity was detectable in all SCR mice within the bone marrow, liver and lungs, whereas shTAK mice only had minimal bioluminescence activity ( Figure . D and . E). Kaplan Meier curves indicated that SCR mice survived only for weeks ( Figure . F) , with leukemia penetrance in bone marrow, blood, spleen and liver ( Supplementary Figure . B and . C). In contrast, TAK knockdown resulted in a signi cantly improved survival (p < . ) ( Figure . F ). E ciency of TAK knockdown at day of sacri ce of some of the shTAK mice was lower than at the day of injection, suggesting that leukemia developed due to improper knockdown in these cells ( Supplementary  Figure . D) . In the % of the shTAK mice that did survive throughout the
Figure . : Di erence in sensitivity to TAK inhibition between normal bone marrow CD + cells versus AML CD + cells
A) NBM CD + cells (n = ) were incubated with nM AZ-TAK for hrs and a er weeks CFCs were determined B) Cord blood CD + cells were transduced with hairpins targeting TAK ; a er two weeks CFCs were determined C) AML CD + cells (n = ) and NBM CD + cells (n = ) were incubated with nM AZ-TAK ; a er hrs cell death was quanti ed by Annexin V staining experiment, no leukemic cells could be detected in blood, bone marrow, liver and spleen at the time these mice were sacri ced. An impaired homing of the transduced cells is unlikely responsible for the observed ndings since MOLM cells transduced with shTAK had a comparable CXCR expression level as the control cells ( Supplementary Figure . A) . In addition no di erence in migration to SDF was observed between both cell populations. (Supplementary Figure . B) .
ese data indicate that targeting TAK strongly impairs leukemia development in vivo and results in a signi cantly improved survival.
. D Evasion of apoptosis is one of the hallmarks during the development of cancer [ ].
Overexpression of multiple anti-apoptotic genes of the mitochondrial related BCL-
Figure . : TAK inhibition results in impaired leukemia development and increased survival in a MOLM xenogra model
A) Schematic representation of mouse experiment B) Sorting strategy of MOLM luciferase GFP positive cells transduced with either control mCherry vector or shTAK mCherry hairpin C) Chimerism levels in peripheral blood a er two weeks of injection of MOLM luciferase GFP/SCR mCherry cells or MOLM luciferase GFP/shTAK mCherry cells D) Bioluminescence pictures of SCR mice and shTAK mice E) Quanti cation of bioluminescence assay of SCR mice (n = ) and shTAK mice (n = ) F) Survival curve of SCR mice and shTAK mice family has been related to the development and or maintenance of AML and is of prognostic signi cance for the treatment outcome of this patients group [ -] . By comparing the apoptotic gene pro le of AML CD + cells versus normal CD + cells, we observed a high expression of several anti-apoptotic genes and, surprisingly, also some pro-apoptotic genes ( Supplementary Table ) . is has previously been observed in an independent cohort of AML and chronic myeloid leukemia patients [ , ] . It is assumed that the increased expression of anti-apoptotic genes, leading to oncogene addiction, is counterbalanced by elevated expression of pro-apoptotic genes, thus creating a "primed to cell death" status [ ]. In our present study, we observed increased expression of TAK in a large panel of AML CD + cells at RNA and protein level. Notably, TAK expression was recently shown to be part of a gene expression signature that de nes AML stem cells [ ]. ese ndings led us hypothesize that TAK might play an important role in AML stem cell maintenance.
e results of the present study indicate that TAK is highly relevant for the in vitro and in vivo survival of AML cells. TAK inhibition by genetic or pharmacologic inhibition strongly triggered cell death in AML CD + cells.
We observed that the pro-survival function of TAK was largely dependent on NF-κB activity, and less dependent on MEK, p and JNK activity, although all these pathways are triggered by TAK activation. NF-κB inhibition not only phenocopied the e ects observed with the TAK inhibitors, but cell death upon TAK inhibition could also be partially rescued by overexpression of NF-κB. It has been demonstrated that NF-κB activity is elevated in patient AML blasts and AML CD + cells compared to normal CD + cells, in part due to the autocrine and paracrine production of growth factors [ , , ] . So far it appears that the enhanced NF-κB expression in AML is a more general result of the malignant transformation and is not related to speci c AML subtypes or genetic abnormalities. It was recently demonstrated that NF-κB is activated in several leukemia mouse model systems including MLL-ENL and MOZ-TIF , and in the double hit model of BCR-ABL with NUP -HOXA . Moreover, in these studies the constitutive activation of NF-κB a ected the primitive leukemic stem cell fraction by expanding the numbers of leukemic initiating cells [ -] .
An important mediator for the constitutive activation of NF-κB is the autocrine production of TNFα by leukemic cells [ ]. Apparently, the transforming events triggered by various mutated genes favor pathways with a pro-survival signature, which are subsequently highly relevant for tumor maintenance. An alternative pathway for NF-κB activation might be the TRAF and Interleukin Receptor Associated Kinase-(IRAK ), which are interacting proteins and mediators of Toll-like (TLR) and Interleukin-(IL-) receptors. Activation of TLR or IL-R results in phosphorylation of IRAK , leading to binding and activation of TRAF . erea er, TAK will be phosphorylated, resulting in the subsequent activation of NF-κB. Recently, it was shown that IRAK is overexpressed and highly activated in high-risk MDS and AML [ ]. Inhibition of IRAK exhibited an impaired expansion and apoptosis and the co-treatment with BCL inhibitors eliminated the MDS clones.
Multiple transcriptome data sets of AML and normal CD + cells, including ours, indicate that besides TAK , TRAF and IL RAP are also signi cantly over-expressed in AML CD + cells [ , , -] , suggesting an ongoing activation of these pathways, subsequently leading to pro-survival signals. e higher expression of TAK in AML CD + cells compared to normal CD + cells suggests that leukemic cells are more dependent on this pathway than normal CD + cells for their survival, indicating a potential therapeutic window for drug targeting. e in vitro results of the TAK inhibitor are in line with these data, showing a di erence in susceptibility for leukemic versus normal cells. Apparently, this type of NF-κB inhibition is more e ective than NF-κB inhibition by proteasome inhibition [ , ] .
However, it cannot be excluded that other pathways besides NF-κB are a ected, since NF-κB overexpression could only partially rescue the phenotype. In addition, knockout of the components of the NF-κB complex, p /RelA and p /RelB, results in a signi cant decline in HSCs frequency [ , ] , but the phenotypes appear to be less severe in comparison to the TAK knockout mice [ ].
ese results are in line with the ndings that di erent pathways converge at TAK and that various pathways, including NF-κB, are activated downstream of TAK . In summary, our data demonstrate that TAK is a critical component in leukemic stem cell maintenance and might be an innovative target for patient treatment. [ ] E. Omori, S. Morioka, K. Matsumoto, and J. Ninomiya-Tsuji. TAK regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. Journal of Biological Chemistry, Figure . : TAK inhibition in AML xenogra model A) Relative expression of TAK in MOLM Luc GFP cells transduced with SCR vector or shTAK vector before injection B) Example of chimerism level detection (GFP + mCherry + CD + CD + cells) in SCR mice C) Chimerism levels of SCR mice after sacri ce D) Expression of TAK in SCR and shTAK mice determined by QPCR Figure . : Migration of shTAK MOLM cells A) MOLM cells were transduced with shTAK or SCR vector and two days later, CXCR expression levels of MOLM SCR and shTAK cells were determined by FACS B) A er two days of transduction, migration potential of these cells was evaluated by a migration assay to ng/mL SDF-
